Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Beyond research, the CDC plays a transformative role in shaping Malaysia’s clinical trial ecosystem — training investigators, ...

The game is afoot in the obesity space as GLP-1 rivals Eli Lilly and Novo Nordisk take their showdown to a new level. Lilly ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

Our writer explains why he just added to a big loser to his Stocks and Shares ISA portfolio, despite it going against one of ...

With more than 3,500 students, Brockton High School is the biggest high school in Massachusetts and become known in recent years for chronic understaffing. Mirroring the nickname of its sports teams, ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...